Michelle P. Dickey, MS, APRN, FNP-BC, PNP-BC

171. Efficacy and Immunogenicity of WRSs2, a Live Attenuated Shigella sonnei Vaccine Candidate, to Protect Against Shigellosis After Challenge with a Wild-type S. sonnei strain 53G. Frenck, RW; Rouphael, N; Baqar, S; Dickey, M; Smith, V; El-Khorazaty, J; Mcneil, M; Quigley, CM; Scherer, E; Fraser, J; Heard, S; Suvarnapunya, A; Cato, K; Venkatesan, M. Open Forum Infectious Diseases. 2026; 13(Supplement_1):ofaf695.001.

Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study. Frenck, RW; Naficy, A; Feser, J; Dickey, MP; Leyva-Grado, VH; Egan, MA; Chen, T; Eldridge, JH; Sciotto-Brown, S; Hermida, L; Innis, BL; Aponte, JJ; Hamm, S; Rathi, N. The Lancet. 2025; 406(10521):2792-2803.

Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. El Sahly, HM; Yildirim, I; Frey, SE; Winokur, P; Jackson, LA; Bernstein, DI; Creech, CB; Chen, WH; Rupp, RE; Whitaker, JA; Ortiz, JR; Berman, MA; Weiss, J; Wegel, A. Journal of Infectious Diseases. 2024; 229(2):327-340.

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. Lyke, KE; Atmar, RL; Dominguez Islas, C; Posavad, CM; Deming, ME; Branche, AR; Johnston, C; El Sahly, HM; Edupuganti, S; Mulligan, MJ; Serebryannyy, L; Beigel, JH; Montefiori, DC; Roberts, PC. npj Vaccines. 2023; 8(1):98.

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Lyke, KE; Atmar, RL; Islas, CD; Posavad, CM; Szydlo, D; Paul Chourdhury, R; Deming, ME; Eaton, A; Jackson, LA; Branche, AR; Suthar, MS; Roberts, PC; Beigel, JH; Montefiori, DC. Cell Reports Medicine. 2022; 3(7):100679.

Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. Ortiz, JR; Spearman, PW; Goepfert, PA; Cross, K; Buddy Creech, C; Chen, WH; Parker, S; Overton, ET; Dickey, M; Logan, HL; Wegel, A; Neuzil, KM. Vaccine. 2022; 40(23):3253-3262.

Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. Frenck, RW; Conti, V; Ferruzzi, P; Ndiaye, AGW; Parker, S; Mcneal, MM; Dickey, M; Granada, JP; Cilio, GL; De Ryck, I; Rappuoli, R; Saul, A; Martin, LB; Podda, A. EClinicalMedicine. 2021; 39:101076.

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Scaggs Huang, F; Bernstein, DI; Slobod, KS; Portner, A; Takimoto, T; Russell, CJ; Meagher, M; Jones, BG; Sealy, RE; Coleclough, C; Mcneal, M; Makowski, M; Nakamura, A; Hurwitz, JL. Human Vaccines & Immunotherapeutics. 2021; 17(2):554-559.

Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G. Clarkson, KA; Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Weerts, HP; Heaney, CD; Mcneal, M; Detizio, K; Parker, S; Hoeper, A; Bourgeois, AL; Porter, CK; Venkatesan, MM; Kaminski, RW. mSphere. 2020; 5(5).

Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G. Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Kaminski, RW; Clarkson, KA; Mcneal, M; Lynen, A; Parker, S; Hoeper, A; Mani, S; Fix, A; Maier, N; Venkatesan, MM; Porter, CK. mSphere. 2020; 5(5).